Wednesday, June 18, 2008

RNAi Researchers Galvanized by Advances

Technology's Viability in Drug Development Is Finally Established
Author: Elizabeth Lipp
Publication: Genetic Engineering & biotechnology News
Publisher: Mary Ann Liebert, Inc. publishers
Date: Jun 1, 2008
Copyright © 2008 GEN Publishing

Article Link:

Notable Quotables:

“Long dsRNAs have been employed for many years as a means to modulate gene expression in plants, yeast, and C. elegans,” noted Mark Behlke, M.D., Ph.D., svp of molecular genetics and CSO at Integrated DNA Technologies (IDT;
“Similar attempts in higher organisms failed due to interferon activation, however we now know that short RNA duplexes can be safely used in mammalian systems both in vitro and in vivo. The technology has rapidly matured, thanks in large part to all that was learned over the past 20 years using antisense oligonucleotides. RNAi is now routinely employed in vivo as an experimental tool and numerous groups are vigorously pursing the use of RNAi compounds as therapeutics. Several siRNA drugs are already in clinical trials and more are in preclinical development.”

No comments: